Celladon reports negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure
Celladon announced its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® versus placebo. April 26, 2015